Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Status:
Terminated
Trial end date:
2017-07-28
Target enrollment:
Participant gender:
Summary
Primary objective:
To assess the efficacy of I10E administered at a reduced maintenance dose in sustaining CIDP
response after an initial 6-month treatment in PRISM study. (I10E-1302).
Secondary objective:
To assess the safety of I10E in this patient population.
Phase:
Phase 3
Details
Lead Sponsor:
Laboratoire français de Fractionnement et de Biotechnologies